CN111972548A - Immunopotentiator for pigs - Google Patents
Immunopotentiator for pigs Download PDFInfo
- Publication number
- CN111972548A CN111972548A CN202010890497.4A CN202010890497A CN111972548A CN 111972548 A CN111972548 A CN 111972548A CN 202010890497 A CN202010890497 A CN 202010890497A CN 111972548 A CN111972548 A CN 111972548A
- Authority
- CN
- China
- Prior art keywords
- parts
- immunopotentiator
- pigs
- vitamin
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000091 immunopotentiator Effects 0.000 title claims abstract description 44
- 241000282887 Suidae Species 0.000 title claims abstract description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 76
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 36
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 36
- 239000011718 vitamin C Substances 0.000 claims abstract description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 34
- 239000008103 glucose Substances 0.000 claims abstract description 34
- 241001061264 Astragalus Species 0.000 claims abstract description 33
- 235000006533 astragalus Nutrition 0.000 claims abstract description 33
- 150000004676 glycans Chemical class 0.000 claims abstract description 33
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 33
- 239000005017 polysaccharide Substances 0.000 claims abstract description 33
- 210000004233 talus Anatomy 0.000 claims abstract description 33
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims description 7
- 230000036039 immunity Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 239000003640 drug residue Substances 0.000 abstract description 3
- 230000001976 improved effect Effects 0.000 abstract description 3
- 239000000419 plant extract Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract description 2
- 235000015277 pork Nutrition 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000008799 immune stress Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000007106 Crataegus suborbiculata Nutrition 0.000 description 1
- 241000073432 Crataegus suborbiculata Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 235000013202 a hawthorn Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
Abstract
The invention relates to an immunopotentiator for pigs, which comprises the following components, by weight, 45-55 parts of vitamin C, 220-320 parts of hawthorn extract, 90-110 parts of astragalus polysaccharide and 700 parts of glucose. According to the technical scheme, the vitamin C, the feed natural plant extract and the glucose are combined together according to the scientific and reasonable proportion to form the immunopotentiator, and immune lymphocytes are induced to become immunocompetent cells, so that the formation of antibodies is promoted, the rapid recovery of the immune function of the pigs after the drug-induced immunosuppressive diseases or the serious epidemic diseases is accelerated, the immunity of the pigs can be remarkably enhanced, the drug residues are reduced or avoided, and the quality of the pork is improved.
Description
Technical Field
The invention relates to the technical field of feeds, in particular to an immunopotentiator for pigs.
Background
With the intensive and large-scale development of animal husbandry, healthy breeding and food safety have attracted extensive attention of people. In particular, the use of large amounts of chemicals, typically antibiotics, has caused problems of bacterial resistance and veterinary drug residues in animal products to be increasingly serious. With the development of modern medicine, cell biology and molecular biology, people gradually realize that the occurrence and development of many animal diseases are closely related to the defects and disorders of the immune system function of the body, and the emphasis of treatment is on the direct killing of exogenous pathogens to adjust the body functions so as to improve the immunity and disease resistance of the body, so that the application of immunopotentiators attracts attention. Therefore, the role of animal immunopotentiators in promoting healthy breeding has been more and more widely regarded.
The animal immunopotentiator is used for enhancing the nonspecific and specific immunity of an animal body in a non-specific way through different action modes, such as enhancing the phagocytic function of macrophages, enhancing the function of immunocompetent cells, enhancing the immunogenicity and stability of antigen substances and the like.
The vaccine is a main mode for enhancing the immunity of the pigs, plays an extremely important role in preventing, controlling and eliminating infectious diseases, and on one hand, the immunization protects the animal organism from being invaded by pathogens, and on the other hand, the immunization also serves as a special stress factor to cause immune stress and generate certain damage to the organism. After the pigs are inoculated with the vaccine, some pigs have stress phenomena of food reduction, food deprivation, mental depression or body temperature rise and the like, so that the growth and the production performance of the pigs are influenced, and the death of a few pigs is possibly caused. The pig immune stress not only causes economic loss, but also brings resistance to the pig immune prevention work.
At present, in many pig farms, after pigs are subjected to immune stress, the pigs are treated by immune stress medicines such as dexamethasone, prednisone and the like, but the immunopotentiator of the western medicine is remained in the bodies after being used by the pigs and influences the health of human bodies after being eaten.
Based on this, a porcine immunopotentiator was studied and developed.
Disclosure of Invention
The invention aims to: the technical problem of one of the prior art is solved, the pig immunopotentiator is provided, and the technical problems of drug residue and the like existing in the prior art of using western medicine intensifier to improve the immunity of pigs are solved.
An immunopotentiator for pigs comprises the following components, by weight, 45-55 parts of vitamin C, 320 parts of hawthorn extract, 90-110 parts of astragalus polysaccharide and 700 parts of glucose.
In the technical scheme, the immunopotentiator is prepared from vitamin C, a feeding natural plant extract, specifically a hawthorn extract and astragalus polysaccharide as main components.
Vitamin C, also known as ascorbic acid, is involved in amino acid metabolism and synthesis of neurotransmitters, collagen and interstitial tissue. Can reduce capillary permeability, promote absorption of iron in intestinal tract, enhance resistance of organism to infection, and enhance liver detoxicating function. Can obviously reduce the incidence of vitamin C deficiency, fever and chronic consumptive diseases.
The fructus crataegi extract mainly contains citric acid, has effects of resolving food stagnation, activating qi-flowing and removing blood stasis, and can rapidly eliminate food damage, abdominal distention, dyspepsia, etc.
The astragalus polysaccharide has the functions of invigorating qi and raising yang, consolidating superficial resistance and arresting sweating, inducing diuresis and reducing edema, detoxifying and expelling pus, healing sore and promoting granulation and the like, and can quickly eliminate the symptoms of lung and spleen qi deficiency, middle-qi sinking, superficial deficiency and spontaneous sweating, qi deficiency edema, sore and carbuncle which are difficult to ulcerate, chronic ulceration and non-healing and the like caused by vivotoxin.
Glucose, which can be used to supplement energy and body fluids, for the purpose of inadequate food intake or loss of large amounts of body fluids due to various causes; the compound feed can be used for feeding sows after delivery, can cover the bitter taste of the medicine when being mixed with the medicine, maintains the feed intake of a swinery, and can play a role in quickly recovering the body temperature of the swinery when the low-temperature swinery is taken by irrigation or intravenous drip of glucose; meanwhile, the feed also has the function of supplementing energy, and when the sick pigs suffer from high fever and anorexia or are abolished, glucose is added into drinking water for energy supply, so that the recovery of the immunity of the pigs is promoted.
In the technical scheme, the immunopotentiator for pigs is prepared by combining the components of vitamin C, hawthorn extract, astragalus polysaccharide, glucose and the like according to a scientific and reasonable proportion. Besides the functions of each component, the vitamin C is also called ascorbic acid, the hawthorn extract contains citric acid as a main component, both are acidic substances, and the two are added together, so that the pH value of gastric contents of pigs can be reduced, the pH value of the gastric contents is relatively stable, the functions of improving the activity of digestive tract enzymes and the digestibility of nutrient substances are realized, the structure of gastrointestinal microbial flora can be regulated, the infection chance of pathogenic microorganisms is reduced, the propagation of the pathogenic microorganisms is inhibited, and the probiotics are propagated. Meanwhile, the composition can improve the internal environment, promote the synthesis of erythrocyte C36 receptor to be accelerated, and is beneficial to regulating the reaction of an immune system, thereby exerting the cellular immune function.
In addition, the vitamin C has the functions of enhancing the resistance of the body to infection and enhancing the liver detoxification function, the astragalus polysaccharide also induces the pig to generate interferon, regulates the body immunity and promotes the generation of antibodies, and the vitamin C and the astragalus polysaccharide have strong complementary effects and obvious synergistic effect.
The components are combined, so that the anti-infection capability of the body can be obviously enhanced, and various infectious diseases of the pig can be purified.
Furthermore, in order to better realize the invention, the immunopotentiator for the pig comprises the following components, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
Furthermore, in order to better realize the invention, the immunopotentiator for the pig comprises the following components, by weight, 45 parts of vitamin C, 220 parts of hawthorn extract, 90 parts of astragalus polysaccharide and 645 parts of glucose.
Furthermore, in order to better realize the invention, the immunopotentiator for the pig comprises the following components, by weight, 55 parts of vitamin C, 320 parts of hawthorn extract, 110 parts of astragalus polysaccharide and 550 parts of glucose.
Furthermore, in order to better realize the invention, the immunopotentiator for the pig comprises the following components, by weight, 45-55 parts of vitamin C, 320 parts of hawthorn extract, 90-110 parts of astragalus polysaccharide and 700 parts of glucose.
Furthermore, in order to better realize the invention, the immunopotentiator for the pig comprises the following components, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
Furthermore, in order to better realize the invention, the immunopotentiator for the pig comprises the following components, by weight, 55 parts of vitamin C, 320 parts of hawthorn extract, 110 parts of astragalus polysaccharide and 515 parts of glucose.
Compared with the prior art, the immunopotentiator for pigs provided by the invention has the following advantages and effects:
according to the technical scheme, the vitamin C, the feeding natural plant extract and the glucose are combined together according to the scientific and reasonable proportion to form the immunopotentiator, and the immunopotentiator can be used by drinking water or mixing with feed, so that the pH value of stomach contents of pigs can be reduced, the structure of gastrointestinal microbial flora is adjusted, the propagation of pathogenic microorganisms is inhibited, and probiotics are propagated. Is helpful for regulating the reaction of immune system, inducing the pig to produce interferon, regulating the immunity of the organism, promoting the generation of antibody, and remarkably purifying various infectious diseases of the pig. Thereby reducing or avoiding drug residue and improving the pork quality.
Detailed Description
The technical solutions of the present invention are described in further detail below, but the scope of the present invention is not limited to the following.
Example 1:
an immunopotentiator for pigs comprises, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
The preparation method comprises the following steps: weighing and uniformly mixing the vitamin C, the hawthorn extract, the astragalus polysaccharide and the glucose according to parts by weight.
The immunopotentiator prepared in this example was added in an amount of 100g in 100L of water, or 2kg in 1 ton of feed.
Example 2:
an immunopotentiator for pigs comprises, by weight, 45 parts of vitamin C, 220 parts of hawthorn extract, 90 parts of astragalus polysaccharide and 645 parts of glucose.
The preparation method comprises the following steps: weighing and uniformly mixing the vitamin C, the hawthorn extract, the astragalus polysaccharide and the glucose according to parts by weight.
The immunopotentiator prepared in this example was added in an amount of 100g in 100L of water, or 2kg in 1 ton of feed.
Example 3:
an immunopotentiator for pigs comprises, by weight, 55 parts of vitamin C, 320 parts of hawthorn extract, 110 parts of astragalus polysaccharide and 515 parts of glucose.
The preparation method comprises the following steps: weighing and uniformly mixing the vitamin C, the hawthorn extract, the astragalus polysaccharide and the glucose according to parts by weight.
The immunopotentiator prepared in this example was added in an amount of 100g in 100L of water, or 2kg in 1 ton of feed.
Example 4:
an immunopotentiator for pigs comprises, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
The preparation method comprises the following steps: weighing and uniformly mixing the vitamin C, the hawthorn extract, the astragalus polysaccharide and the glucose according to parts by weight.
The immunopotentiator prepared in this example was added in an amount of 100g in 100L of water, or 2kg in 1 ton of feed.
Example 5:
an immunopotentiator for pigs comprises, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
The preparation method comprises the following steps: weighing and uniformly mixing the vitamin C, the hawthorn extract, the astragalus polysaccharide and the glucose according to parts by weight.
The immunopotentiator prepared in this example was added in an amount of 100g in 100L of water, or 2kg in 1 ton of feed.
Example 6:
an immunopotentiator for pigs comprises, by weight, 55 parts of vitamin C, 320 parts of hawthorn extract, 110 parts of astragalus polysaccharide and 515 parts of glucose.
The preparation method comprises the following steps: weighing and uniformly mixing the vitamin C, the hawthorn extract, the astragalus polysaccharide and the glucose according to parts by weight.
The immunopotentiator prepared in this example was added in an amount of 100g in 100L of water, or 2kg in 1 ton of feed.
The pig immunopotentiator prepared in example 3 was used for the following verification.
The test method comprises the following steps:
the test animals are 200 healthy weaned piglets with average weight of (7.98 +/-0.12) kg in a farm belonging to the Sichuan Proliter agricultural development Limited company, and the weight difference is not significant through statistical analysis. By adopting a single-factor randomized design, 200 healthy weaned piglets are divided into 2 groups, namely a control group and a test group, according to the half of a male piglet and a female piglet, each group has 10 repetitions, and each group has 10 repetitions. The test group was supplemented with the product of the invention prepared in example 2, and the control group was not supplemented with the product of the invention. The feed additive is continuously fed for 30 days, and compared with a control group, the following effects can be obtained by using the feed additive:
the weight, feed intake, number of diarrhea and number of respiratory tract disease episodes at the end of the piglet trial were recorded.
The test result shows that the daily gain of the piglets is greatly improved compared with the control group by adding the product into the daily ration of the weaned piglets; the feed conversion ratio is obviously reduced; the diarrhea rate and the respiratory disease incidence of the piglets are obviously reduced.
Example 3 of the present invention the effect test of the feed additive in lactating sows
Feeding trials for 21 days were conducted in a pig farm under Sichuan Proliter agricultural development Co. The test adopts a single-factor comparison design, 50 healthy lactating sows with farrowing number similar to the average birth weight and 2 or 3 births are randomly selected and divided into 2 groups, namely a test group and a control group, and each group has 25 sows.
Wherein: the test group was dosed with the product prepared in example 3, and the control group was not dosed with the product of the invention.
The weight of weaned piglets, the number of deaths, the number of diarrhea and the number of respiratory diseases are recorded.
The test result shows that the body weight of the weaned piglets is greatly improved compared with that of a control group by adding the product into the daily ration of the lactating sow; the diarrhea rate and the respiratory disease incidence of the piglets are obviously reduced.
The above two tests show that: the product of the invention can improve the body immunity of sows and piglets, obviously reduce the diarrhea rate and respiratory disease incidence of piglets, and improve the culture quality and benefit.
The above-mentioned embodiments only express the specific embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (8)
1. An immunopotentiator for pigs is characterized by comprising the following components, by weight, 45-55 parts of vitamin C, 220-320 parts of hawthorn extract, 90-110 parts of astragalus polysaccharide and 700 parts of glucose.
2. The immunopotentiator for pigs according to claim 1, which comprises the following components, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
3. The immunopotentiator for pigs according to claim 1, which comprises the following components, by weight, 45 parts of vitamin C, 220 parts of hawthorn extract, 90 parts of astragalus polysaccharide and 645 parts of glucose.
4. The immunopotentiator for pigs according to claim 1, which comprises the following components, by weight, 55 parts of vitamin C, 320 parts of hawthorn extract, 110 parts of astragalus polysaccharide and 515 parts of glucose.
5. An immunopotentiator for pigs is characterized by comprising, by weight, 45-55 parts of vitamin C, 320 parts of hawthorn extract, 90-110 parts of astragalus polysaccharide and 700 parts of glucose.
6. The porcine immunopotentiator according to claim 5, wherein: comprises the following components, by weight, 45-55 parts of vitamin C, 320 parts of hawthorn extract, 90-110 parts of astragalus polysaccharide and 700 parts of glucose.
7. The porcine immunopotentiator according to claim 5, wherein: the health-care food comprises, by weight, 50 parts of vitamin C, 250 parts of hawthorn extract, 100 parts of astragalus polysaccharide and 600 parts of glucose.
8. The porcine immunopotentiator according to claim 5, wherein: the health-care food comprises, by weight, 55 parts of vitamin C, 320 parts of hawthorn extract, 110 parts of astragalus polysaccharide and 515 parts of glucose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010890497.4A CN111972548A (en) | 2020-08-29 | 2020-08-29 | Immunopotentiator for pigs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010890497.4A CN111972548A (en) | 2020-08-29 | 2020-08-29 | Immunopotentiator for pigs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111972548A true CN111972548A (en) | 2020-11-24 |
Family
ID=73440774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010890497.4A Pending CN111972548A (en) | 2020-08-29 | 2020-08-29 | Immunopotentiator for pigs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111972548A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114568589A (en) * | 2022-03-24 | 2022-06-03 | 广东科润生物制药有限公司 | Composite vitamin composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110004A (en) * | 2012-12-07 | 2013-05-22 | 济南和美华饲料有限公司 | Biological feed for pigs |
| CN105535078A (en) * | 2015-12-28 | 2016-05-04 | 成都华罗生物科技有限公司 | Pharmaceutical composition for improving productivityand immunity of sow and preparation method and application of pharmaceutical composition |
| CN110604226A (en) * | 2018-06-15 | 2019-12-24 | 江苏奥迈生物科技有限公司 | Diarrhea-preventing growth-promoting composite feed additive for weaned piglets and preparation method thereof |
-
2020
- 2020-08-29 CN CN202010890497.4A patent/CN111972548A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110004A (en) * | 2012-12-07 | 2013-05-22 | 济南和美华饲料有限公司 | Biological feed for pigs |
| CN105535078A (en) * | 2015-12-28 | 2016-05-04 | 成都华罗生物科技有限公司 | Pharmaceutical composition for improving productivityand immunity of sow and preparation method and application of pharmaceutical composition |
| CN110604226A (en) * | 2018-06-15 | 2019-12-24 | 江苏奥迈生物科技有限公司 | Diarrhea-preventing growth-promoting composite feed additive for weaned piglets and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张世昌，等: "复方中草药添加剂对断奶仔猪生长性能、抗氧化和免疫器官指数的影响", 《畜牧与兽医》 * |
| 李培发: "黄芪多糖VC新霉素预混剂对仔猪的保健效果", 《当代畜牧》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114568589A (en) * | 2022-03-24 | 2022-06-03 | 广东科润生物制药有限公司 | Composite vitamin composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101406166B (en) | Segregated early weaning method of piglet | |
| CN104543411B (en) | Yeast complex additive with high-efficiency food attraction and immunological enhancement functions | |
| CN108079284B (en) | Medicine for improving sow production performance and preparation method and application thereof | |
| CN107114584B (en) | Feed additive for lactating sows and preparation and use methods thereof | |
| CN106509440A (en) | Health-care feed additive for multiparous sows | |
| CN103947905A (en) | Heat-stress-resistant traditional Chinese medicine microbial feed additive specially used for sows, and preparation method of feed additive | |
| CN101696444B (en) | Polypeptide extract as well as preparation method and application thereof | |
| CN108541817A (en) | One broad sow compound premix | |
| CN108077622B (en) | Additive for improving production performance of sows, preparation method of additive and mixed feed containing additive | |
| CN103598437B (en) | For improving the feed of Layer Production Performance | |
| CN104161205B (en) | A kind of sow feed additive and application thereof preventing yellow and white dysentery of piglet | |
| CN110192595A (en) | A kind of composite microorganism additive agent for milk cattle feed stuff and its preparation method and application | |
| CN106889327A (en) | A kind of milk powder for sucking pig and preparation method thereof | |
| CN111972548A (en) | Immunopotentiator for pigs | |
| CN104664168B (en) | A kind of piglet specific complex vitamin microemulsion preparation and its preparation method and application | |
| CN110192653A (en) | A kind of preparation method of pregnant and lying-in women and children special-purpose probiotics | |
| CN108887474A (en) | A kind of compound preparation of resisting stress and preparation method thereof | |
| CN112167444A (en) | Feed additive for improving vitality immunity and promoting metabolism | |
| CN102228181A (en) | Composition eaten by cancer patients and containing oligopeptide and chitosan oligosaccharide | |
| CN113100342B (en) | Additive for promoting growth of piglets and preparation method thereof | |
| CN107259090A (en) | A kind of feed for keeping and improving peacock selenium content in egg and preparation method thereof | |
| CN108935999A (en) | A kind of feed and its feed addictive promoting sow lactation and heat | |
| CN104381715A (en) | Piglet feed additive | |
| CN106721254A (en) | The health additive and its technique of one boar and application | |
| CN111772035A (en) | Compound additive for improving immunity of piglets and complete formula feed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |